Currently, Novavax, Inc.’s (NVAX) stock is trading at $5.57, marking a gain of 2.11% from last night’s close. At this price, the stock is -51.01% below its 52-week high of $11.36 and 57.54% above its 52-week low of $3.53. Based on the past 30-day period, the stock price is -8.62% below the high and +45.10% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, NVAX’s SMA-200 is $6.52.
As well, it is important to consider NVAX stock ratios such as price-to-sales, which is currently 0.79.
How does Novavax, Inc. (NVAX) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 6 brokerage firms that recommend the stock as a Moderate Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 3.50 in simple terms.
Novavax, Inc. (NVAX): Earnings History
If we examine Novavax, Inc.’s recent earnings history, in the last quarter ended on 12/30/2023, it posted adjusted earnings per share of -$1.44, beating the consensus of -$0.45. In other words, it beat the consensus by -$0.99, resulting in a -220.00% surprise. In the 3 months period before the previous quarter which was closed on 12/30/2023, the stock recorded adjusted earnings per share of -$1.44 in contrast with the Outlook of -$0.45. That was a difference of -$0.99 and a surprise of -220.00%.
Novavax, Inc. (NVAX): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 5 different analysts, who are expecting earnings to fall in between the range of -0.14 and -1.48 with an average Earnings Estimate of -0.75 which is in contrast with the last year earnings estimate of -3.41 and also replicates 78.01% growth rate year over year.
Novavax, Inc. (NASDAQ: NVAX) Ownership Details
I will give a breakdown of the key shareholders in Novavax, Inc. (NVAX). Recent figures show that the company’s insiders hold 4.97% of shares. A total of 283 institutional investors hold shares in the company, making 56.21% of its stock and 59.14% of its float.
Jun 29, 2023, it was reported that the Company’s largest institutional holder is State Street Corporation holding total of 11.68 million shares that make 12.37% of the company’s total number of shares and are currently priced at 86.78 million.
The securities firm Vanguard Group Inc holds 10.57 million shares of NVAX, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 11.20%, and the holding percentage of shares is valued at 78.55 million.
An overview of Novavax, Inc.’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Novavax, Inc. (NVAX) traded 12,300,208 shares per day, with a moving average of $4.92 and price change of +1.50. With the moving average of $4.58 and a price change of +0.59, about 9,512,014 shares changed hands on average over the past 50 days. Finally, NVAX’s 100-day average volume is 8,205,754 shares, alongside a moving average of $5.25 and a price change of -1.10.
